scholarly journals Differential expression of trophinin associated protein in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding trophinin associated protein, TROAP, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. TROAP expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. TROAP expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of TROAP is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. TROAP may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of sarcospan in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding sarcospan, SSPN, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. SSPN expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. SSPN expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of SSPN is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. SSPN may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of phosphodiesterase 5A in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding phosphodiesterase 5A, PDE5A, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. PDE5A expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. PDE5A expression correlated with progression-free survival in patients with p53 mutant ovarian cancer. These data indicate that expression of PDE5A is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PDE5A may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of dystrophin in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published and public microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding dystrophin, DMD, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. DMD expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. DMD expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of DMD is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. DMD may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of seizure-related 6 homolog-like 2 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding seizure-related 6 homolog-like 2, SEZ6L2, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. SEZ6L2 expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. SEZ6L2 expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of SEZ6L2 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. SEZ6L2 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of prune homolog 2 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published and public microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding prune homolog 2, PRUNE2, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. PRUNE2 expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. PRUNE2 expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of PRUNE2 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PRUNE2 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of ectodermal-neural cortex 1 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published and public microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding ectodermal-neural cortex 1, ENC1, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. ENC1 expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. ENC1 expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of ENC1 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. ENC1 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of RAB9B in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding RAB9B, member RAS oncogene family, RAB9B, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. RAB9B expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. RAB9B expression correlated with progression-free survival in patients with p53 mutant ovarian cancer. These data indicate that expression of RAB9B is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. RAB9B may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of myomesin 1 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding myomesin 1, MYOM1, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. MYOM1 expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. MYOM1 expression correlated with progression-free survival in patients with ovarian cancer. These data indicate that expression of MYOM1 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. MYOM1 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of transmembrane 7 superfamily member 2 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding transmembrane 7 superfamily member 2, TM7SF2, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. TM7SF2 expression was significantly higher in high-grade serous ovarian tumors relative to normal fallopian tube. TM7SF2 expression correlated with progression-free survival in patients with ovarian cancer whose tumors were mutant for p53. These data indicate that expression of TM7SF2 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. TM7SF2 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

scholarly journals Differential expression of patched domain-containing 1 in human epithelial ovarian cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Expression Profiles ◽  
Gynecologic Cancer ◽  
Gene Expression Profiles ◽  
Progression Free Survival ◽  
High Grade ◽  
Primary Tumors ◽  
Ovarian Cancers

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We performed discovery of genes associated with epithelial ovarian cancer and of the high-grade serous ovarian cancer (HGSC) subtype, using published microarray data (2, 3) to compare global gene expression profiles of normal ovary or fallopian tube with that of primary tumors from women diagnosed with epithelial ovarian cancer or HGSC. We identified the gene encoding patched domain-containing 1, PTCHD1, as among the genes whose expression was most different in epithelial ovarian cancer as compared to the normal fallopian tube. PTCHD1 expression was significantly lower in high-grade serous ovarian tumors relative to normal fallopian tube. PTCHD1 expression correlated with progression-free survival in patients with p53 mutant ovarian cancer. These data indicate that expression of PTCHD1 is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PTCHD1 may be relevant to pathways underlying ovarian cancer initiation (transformation) or progression.

Sign in / Sign up

Export Citation Format

Share Document